Matthew B. Klein Insider Profile

4 Followers
Matthew B. Klein, CEO, Director at PTC Therapeutics, holds 29.43K shares in ClearPoint Neuro (Ticker: CLPT), holds 225.81K shares in PTC Therapeutics (Ticker: PTCT).
tipranks
Matthew B. Klein

Matthew B. Klein
PTC Therapeutics (PTCT)
CEO, Director

Ranked #62,896 out of 99,218 Corporate Insiders

Profitable Transactions

50%
4 out of 8 Profitable Transactions

Average Return

-5.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$10M
96.01%
3.99%
A breakdown of Matthew B. Klein's holdings

Insider Roles

PTC Therapeutics
(PTCT)
CEO, Director
ClearPoint Neuro
(CLPT)
Director
Roles that Matthew B. Klein holds in companies

Most Profitable Insider Trade

Stock:
PTC Therapeutics
(PTCT)
Rating:Informative Sell
Date:Apr 20, 2023 - Apr 20, 2024
Return:+52.90%
The most profitable trade made by Matthew B. Klein

Matthew B. Klein's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
PTC Therapeutics
Apr 22, 2024
CEO, Director
Informative Sell
83.66K
$9.14M
ClearPoint Neuro
May 15, 2024
Director
Uninformative Buy
103.09K
$379.29K
List of latest transactions for each holding click on a transaction to see Matthew B. Klein's performance on stock

Matthew B. Klein insider profile FAQ

What is the percentage of profitable transactions made by Matthew B. Klein?
The percentage of profitable transactions made by Matthew B. Klein is 50%.
    What is the average return per transaction made by Matthew B. Klein?
    The average return per transaction made by Matthew B. Klein is -5.80%.
      What stocks does Matthew B. Klein hold?
      Matthew B. Klein holds: PTCT, CLPT stocks.
        What was Matthew B. Klein’s latest transaction?
        Matthew B. Klein latest transaction was an Uninformative Buy of $103.09K.
          What was Matthew B. Klein's most profitable transaction?
          Matthew B. Klein’s most profitable transaction was an Informative Sell of PTCT stock on April 20, 2023. The return on the trade was 52.90%.
            What is Matthew B. Klein's role in PTC Therapeutics?
            Matthew B. Klein's role in PTC Therapeutics is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.